middl
east
respiratori
syndrom
coronaviru
merscov
lethal
zoonot
pathogen
first
identifi
human
saudi
arabia
jordan
intermitt
sporad
case
commun
cluster
nosocomi
outbreak
merscov
continu
occur
april
decemb
laboratoryconfirm
case
merscov
infect
includ
death
mortal
report
countri
major
report
saudi
arabia
case
death
larg
outbreak
humantohuman
transmiss
occur
largest
riyadh
jeddah
south
korea
merscov
remain
highthreat
pathogen
identifi
prioriti
pathogen
caus
sever
diseas
high
mortal
rate
epidem
potenti
medic
countermeasur
seminar
provid
updat
current
knowledg
perspect
mer
epidemiolog
virolog
mode
transmiss
pathogenesi
diagnosi
clinic
featur
manag
infect
control
develop
new
therapeut
vaccin
highlight
unansw
question
prioriti
research
improv
manag
prevent
past
year
three
lethal
zoonot
diseas
human
caus
novel
coronavirus
sever
acut
repiratori
syndrom
sar
novemb
middl
east
respiratori
syndrom
mer
april
recent
coronaviru
diseas
decemb
three
caus
coronavirus
respect
sarscov
merscov
sarsrel
focus
attent
global
public
health
author
list
blueprint
list
prioriti
pathogen
pandem
potenti
threat
global
health
secur
absenc
effect
treatment
sarscov
first
identifi
human
guangdong
china
novemb
subsequ
spread
rapidli
worldwid
countri
result
human
sar
case
death
mortal
sar
epidem
end
abruptli
juli
human
case
sar
detect
past
year
merscov
first
identifi
caus
human
diseas
isol
lung
sampl
adult
patient
admit
hospit
jeddah
saudi
arabia
sever
pneumonia
die
multiorgan
failur
retrospect
studi
link
merscov
hospit
outbreak
april
jordan
merscov
consid
zoonot
pathogen
merscovinfect
dromedari
camel
anim
sourc
infect
human
unlik
sarscov
contain
within
year
emerg
merscov
continu
circul
caus
human
diseas
intermitt
sporad
case
commun
cluster
nosocomi
outbreak
middl
east
consider
risk
spread
global
sever
outbreak
humantohuman
merscov
tran
mission
occur
largest
outsid
middl
east
occur
south
korea
outbreak
associ
substanti
morbid
mortal
well
substanti
econom
social
health
secur
effect
initi
name
detect
decemb
sequenc
clinic
sampl
cluster
patient
wuhan
china
develop
pneumonia
unknown
caus
outbreak
rapidli
evolv
march
laboratori
confirm
case
death
mortal
outsid
china
case
report
countri
death
seminar
review
current
knowledg
provid
updat
merscov
epidemiolog
virolog
mode
transmiss
pathogenesi
diagnosi
clinic
featur
manag
infect
control
develop
new
therapeut
vaccin
also
highlight
unansw
question
prioriti
research
improv
manag
prevent
merscov
sarscov
member
coronavirida
famili
order
nidoviral
human
coronavirus
gener
caus
mild
respiratori
infect
eg
merscov
like
sarscov
caus
highli
lethal
diseas
human
merscov
larg
singlestrand
positivesens
rna
viru
figur
kb
coronaviru
genom
encod
larg
number
protein
might
confer
versa
tiliti
adapt
new
environ
enhanc
crossspeci
transmiss
merscov
four
structur
protein
spike
protein
envelop
e
protein
membran
protein
nucleocapsid
n
protein
protein
type
transmembran
glycoprotein
locat
trimer
viru
surfac
consist
subunit
crucial
role
bind
fusion
entri
host
cell
subunit
receptor
bind
domain
bind
host
cellular
receptor
dipeptidyl
peptidas
subunit
two
region
heptad
repeat
rearrang
form
sixhelix
bundl
enabl
membran
fusion
e
protein
present
viral
membran
requir
viral
assembl
bud
intracellular
traffick
merscov
enter
host
cell
via
bind
protein
host
cell
receptor
figur
appendix
pp
less
abund
nasal
caviti
epitheli
cell
upper
airway
highli
express
epitheli
cell
distal
airway
type
ii
pneumocyt
lung
alveoli
noncili
bronchial
epitheli
cell
endotheli
cell
haemopoiet
cell
also
wide
express
epitheli
cell
sever
organ
tissu
kidney
intestin
liver
thymu
bone
marrowthu
wide
spread
dissemin
merscov
could
occur
bodi
structur
protein
merscov
coronavirus
deter
mine
use
cryoelectron
microscopi
provid
basi
ration
design
protect
antibodi
therapeut
primari
merscov
infect
defin
laboratoryconfirm
merscov
infect
direct
epidemiolog
link
human
merscov
infect
acquir
outsid
healthcar
facil
presum
direct
indirect
contact
reservoir
hostdromedari
camel
secondari
merscov
infect
defin
laboratoryconfirm
merscov
infect
direct
epidemiolog
link
individu
confirm
probabl
merscov
infect
laboratoryconfirm
merscov
human
infect
origin
primari
human
merscov
infect
remain
unknown
dromedari
camel
host
reservoir
speci
merscov
appendix
pp
human
acquir
merscov
direct
indirect
contact
infect
dromedari
camel
infect
patient
figur
howev
case
infect
commun
report
contact
dromedari
camel
appendix
p
transmiss
merscov
dromedari
camel
human
well
document
arabian
peninsula
extent
transmiss
occur
countri
outsid
arabian
peninsula
requir
definit
experiment
infect
shown
infect
dromedari
shed
merscov
nasal
secret
minim
sign
ill
limit
rhinorrhoea
fullgenom
phylogenet
analysi
indic
evolut
divers
merscov
lineag
camel
caus
human
infect
perpetu
low
barrier
interspeci
transmiss
howev
african
merscov
lineag
camel
import
saudi
arabia
establish
camel
saudi
arabia
indic
potenti
differ
transmiss
dynam
select
pressur
analysi
popul
dynam
show
arabian
virus
maintain
endem
without
introduct
addit
lineag
support
molecular
serolog
studi
dromedaryhuman
interfac
sever
countri
accessori
protein
orf
encod
end
third
end
genom
genom
merscov
bind
cellular
receptor
via
protein
process
host
proteas
expos
fusion
peptid
viral
genom
releas
cytoplasm
translat
host
ribosom
protein
polyprotein
cleav
two
viralencod
proteas
encod
protein
involv
genom
subgenom
replic
transcript
includ
rnadepend
rna
polymeras
rdrp
two
associ
protein
helicas
encod
methyltransferas
exon
protein
requir
genom
fidel
methyltransferas
also
necessari
optim
genom
subgenom
rna
synthesi
merscov
transcript
involv
synthesi
subgenom
rna
encod
structur
accessori
protein
locat
end
genom
subgenom
genom
rna
cotermin
share
leader
sequenc
subgenom
rna
code
structur
accessori
protein
encod
within
n
gene
mark
purpl
line
accessori
protein
believ
immunoevas
properti
essenti
replic
variabl
delet
human
camel
viru
isol
genom
replic
occur
membran
structur
doubl
membran
vesicl
dmv
convolut
membran
cm
vesicl
packet
vp
merg
dmv
form
rough
endoplasm
reticulum
rer
combin
action
lower
right
synthesi
replicasetranscript
complex
rna
encapsid
n
protein
transport
ergic
endoplasm
reticulumgolgi
compart
bud
membran
contain
e
protein
occur
releas
cell
proteas
exonexonucleas
merscovmiddl
east
respiratori
syndrom
coronaviru
mtasemethyltransferas
nendounidovir
uridylatespecif
endoribonucleas
factor
activ
b
cell
ntpasenucleosidetriphosphatas
plpropapainlik
proteas
africa
south
asia
phylogenet
relationship
complet
genom
merscov
strain
obtain
camel
human
publish
epidemiolog
pattern
merscov
human
remain
consist
sinc
merscov
first
identifi
primari
case
often
report
direct
indirect
contact
dromedari
camel
present
across
wide
clinic
spectrum
mild
sever
fulmin
diseas
individu
sever
primari
merscov
infect
often
older
year
comorbid
symptom
present
late
individu
mild
primari
merscov
infect
often
miss
current
surveil
system
sinc
usual
present
healthcar
facil
secondari
case
result
humantohuman
transmiss
among
close
contact
date
secondari
transmiss
occasion
occur
close
contact
individu
laboratoryconfirm
merscov
household
set
healthcar
set
humantohuman
transmiss
occur
patient
patient
healthcar
worker
patient
visitor
approxim
half
merscov
case
report
date
result
humantohuman
transmiss
healthcar
facil
known
risk
factor
merscov
acquisit
transmiss
outbreak
note
panel
mer
patient
data
report
includ
inform
exposur
known
risk
factor
day
symp
tom
onset
day
laboratori
confirm
report
case
asymptomat
infect
exposur
data
includ
travel
histori
merscov
endem
countri
direct
indirect
contact
dromedari
camel
product
contact
human
merscov
infect
visit
healthcar
facil
contain
patient
infect
merscov
risk
factor
acquir
merscov
infect
appendix
pp
merscov
detect
camel
product
eg
raw
milk
meat
blood
urin
birth
product
howev
genom
studi
definit
show
transmiss
product
human
yet
done
human
primari
intestin
epitheli
cell
small
intestin
explant
intestin
tract
highli
suscept
merscov
sustain
viral
replic
infect
mice
transgen
express
host
receptor
histolog
examin
show
merscov
enter
infect
inocul
mice
progress
infect
lung
tissu
indic
develop
sequenti
respiratori
infect
transmiss
via
contact
contamin
hospit
environ
possibl
outbreak
although
genom
studi
provid
evid
base
lack
sinc
environment
contamin
potenti
sourc
infect
prudent
take
precautionari
infect
control
measur
healthcareassoci
outbreak
merscov
affect
inpati
healthcar
worker
visitor
characterist
mer
panel
account
approxim
mechan
underli
pathogenesi
merscov
remain
defin
autopsi
gener
done
either
religi
cultur
reason
prevent
environment
contamin
subsequ
infect
healthcar
worker
therefor
data
histopatholog
chang
patient
merscov
infect
even
sever
diseas
two
autopsi
avail
show
viral
infect
confin
predominantli
respiratori
tract
although
viral
particl
detect
kidney
one
report
ex
vivo
human
kidney
cultur
shown
support
product
merscov
infect
howev
known
whether
infect
organ
contribut
wors
outcom
compar
infect
confin
respiratori
tract
viral
rna
infecti
merscov
detect
blood
least
week
diagnosi
whether
viral
rna
repres
extrapulmonari
infect
clear
sinc
merscov
neutralis
antibodi
detect
serum
time
patient
patholog
chang
lung
includ
evid
focal
haemorrhag
necrotis
pneumonia
exud
diffus
alveolar
damag
indistinguish
find
detect
sever
pneumonia
caus
viral
agent
sever
experiment
infect
anim
model
mer
develop
appendix
p
method
gene
silenc
edit
develop
therefor
like
addit
viral
host
factor
import
merscov
pathogenesi
identifi
merscov
pathogenesi
reflect
balanc
coronavirusinduc
protect
pathogen
host
immun
respons
direct
cytotox
effect
viru
accord
studi
patient
infect
sarscov
mice
anim
infect
experiment
merscov
success
resolut
mer
longterm
protect
reinfect
like
requir
well
coordin
innat
adapt
bcell
tcell
respons
patient
sar
innat
immun
respons
characteris
extend
period
cytokin
secret
eg
correl
delay
antibodi
respons
poor
manag
outcom
prolong
innat
respons
yet
shown
patient
infect
merscov
acut
phase
mer
robust
virusspecif
tcell
respons
detect
patient
sever
moder
diseas
antibodi
tcell
respons
appear
later
diseas
cours
tcell
antibodi
respons
reliabl
detect
week
diagnosi
although
detect
earlier
patient
studi
mer
survivor
show
merscovspecif
antibodi
respons
tend
lower
transient
patient
mild
subclin
diseas
compar
patient
sever
diseas
merscovspecif
antibodi
respons
detect
least
year
contrast
tcell
respons
detect
mer
survivor
least
year
transitori
natur
antibodi
respons
mild
diseas
greater
stabil
tcell
respons
suggest
induct
requir
optim
longterm
protect
measur
enhanc
accuraci
preval
studi
specif
exposur
lead
sporad
merscov
infect
unknown
therefor
imposs
estim
incub
period
primari
case
howev
base
data
case
humantohuman
transmiss
incub
period
median
day
rang
day
median
day
ci
immunocompromis
patient
present
longer
incub
period
day
clinic
present
patient
infect
merscov
rang
asymptomat
mild
upper
respiratori
ill
rapidli
progress
pneumon
respiratori
failur
acut
respiratori
distress
syndrom
septic
shock
multiorgan
failur
fatal
outcom
figur
possibl
distinguish
patient
legitim
asymptomat
merscov
infect
develop
mild
diseas
report
provid
sign
symptom
inform
time
report
mani
individu
remain
asymptomat
wherea
go
develop
mild
diseas
classifi
individu
mild
asymptomat
asymptomatictomild
infect
rate
report
sign
symptom
associ
mer
nonspecif
without
multisystem
involv
thu
could
mistaken
caus
respiratori
tract
gastrointestin
ill
therefor
clinic
diagnosi
mer
easili
miss
patient
mer
typic
present
fever
chill
rigor
headach
nonproduct
cough
sore
throat
arthralgia
myalgia
follow
dyspnoea
associ
symptom
includ
coryza
nausea
vomit
dizzi
sputum
product
diarrhoea
abdomin
pain
patient
mer
present
atyp
symptom
mild
respiratori
ill
without
fever
gastrointestin
ill
preced
develop
ment
pneumonia
pathogen
merscov
antivir
therapeut
includ
hostdirect
therapi
immunebas
therapi
develop
intermedi
host
reservoir
dromedari
camel
vaccin
dromedari
camel
sourc
primari
human
infect
propos
approach
prevent
human
infect
recombin
camelpox
viru
express
protein
shown
induc
neutralis
antibodi
camel
compar
older
camel
juvenil
camel
higher
rate
viral
shed
past
infect
protect
basic
hand
hygien
practic
glove
face
mask
handl
infect
camel
camel
product
pasteuris
camel
milk
avoid
ingest
raw
camel
meat
dairi
product
urin
vaccin
develop
peopl
high
camel
exposur
face
mask
hand
hygien
measur
hcw
famili
contact
occup
expos
peopl
higher
risk
infect
compar
gener
public
human
surveil
focus
diseas
peopl
subclin
asymptomat
infect
could
serv
sourc
infect
suscept
person
comorbid
nosocomi
case
outbreak
diminish
due
institut
stringent
infect
control
measur
still
account
case
human
vaccin
develop
test
animalssom
human
phase
trial
mersmiddl
east
respiratori
syndrom
merscovmiddl
east
respiratori
syndrom
coronaviru
tingl
extrem
similar
syndrom
virusrel
sensori
neuropathi
coinfect
merscov
respiratori
virus
parainfluenza
viru
rhinoviru
influenza
b
viru
respiratori
syncyti
viru
enterovirus
human
meta
pneu
mo
viru
nosocomi
bacteri
infect
report
patient
receiv
intens
care
immunocompromis
patient
comorbid
immunocompromis
patient
patient
chronic
heart
liver
kidney
diseas
present
atyp
featur
longer
incub
period
longer
period
initi
pcr
posit
symptom
onset
persist
prolong
viral
shed
increas
mortal
merscov
caus
sever
diseas
peopl
older
year
chronic
comorbid
diseas
renal
diseas
cancer
chronic
lung
diseas
immunosuppress
diabet
children
yonger
year
merscov
infect
appear
rare
usual
present
mild
diseas
cough
predomin
clinic
symptom
acut
sever
respiratori
ill
ie
fatal
outcom
multiorgan
failur
note
two
report
paediatr
case
boy
age
month
year
comorbid
infantil
nephrot
syndrom
cystic
fibrosi
respect
data
preval
merscov
pregnant
women
limit
case
report
clinic
present
mortal
rate
similar
nonpregn
women
mer
kept
differenti
diagnosi
list
ill
travel
return
home
merscov
endem
area
present
acut
febril
ill
temperatur
ach
pain
headach
cough
dyspnoea
diarrhoea
nausea
vomit
unexplain
leucopenia
white
blood
cell
count
thrombocytopenia
platelet
either
without
promin
respiratori
symptom
import
clinician
alert
possibl
patient
could
mer
healthcar
set
viru
circul
accur
diagnosi
made
infect
control
measur
implement
effici
type
qualiti
clinic
specimen
import
laboratori
diagnosi
merscov
infect
upper
respiratori
tract
specimen
oropharyng
nasopharyng
swab
lower
respiratori
tract
specimen
sputum
endotrach
aspir
lavag
analys
whenev
possibl
patient
mer
might
shed
viru
earli
stage
ill
thu
initi
neg
result
upper
respiratori
sampl
rule
possibl
mer
patient
retest
use
lower
respiratori
tract
sampl
sever
studi
merscov
viral
load
measur
show
upper
respiratori
tract
specimen
lower
viral
load
lower
respiratori
specimen
merscov
rna
detect
blood
urin
stoolbut
much
lower
viral
load
respiratori
tract
clinic
specimen
must
collect
train
staff
use
appropri
person
protect
equipmenteg
take
nasopharyng
oropharyng
specimen
dacron
rayon
swab
specif
design
collect
specimen
virolog
must
use
swab
kit
contain
viru
transport
medium
singl
neg
test
result
exclud
diagnosi
repeat
sampl
test
strongli
recommend
minimum
two
sampl
prefer
lower
respiratori
tract
need
exclud
merscov
initi
assess
confirm
clearanc
viru
respiratori
sampl
collect
sequenti
everi
day
ensu
day
two
consecut
neg
result
least
h
apart
peopl
clinic
recov
guidelin
test
follow
merscov
test
must
perform
appropri
equip
biosafeti
laboratori
staff
train
relev
technic
safeti
procedur
nation
guidelin
laboratori
biosafeti
follow
circumst
three
realtim
rtpcr
rrtpcr
assay
routin
detect
merscov
develop
target
upstream
e
protein
gene
upe
open
read
frame
orf
assay
upe
target
consid
highli
sensit
recommend
screen
assay
assay
consid
sensit
assay
updat
roadmap
merscov
product
develop
list
avail
diagnost
diagnost
development
phase
sever
diagnost
test
develop
acceler
turnaround
time
sampl
analysi
result
rapid
specif
assay
detect
merscov
combin
revers
transcript
loopmedi
isotherm
amplif
techniqu
vertic
flow
visualis
strip
rtlampvf
detect
nucleocapsid
gene
merscov
rtlampvf
assay
provid
detect
merscov
within
min
easier
perform
whorecommend
rrtpcr
method
sever
serolog
assay
avail
detect
merscov
elisa
recombin
spike
immunofluoresc
assay
spike
pseudoparticl
neutralis
microneutralis
assay
case
confirm
serolog
requir
evid
seroconvers
two
sampl
ideal
taken
least
day
apart
screen
eg
elisa
immunofluoresc
assay
neutralis
assay
imag
rang
abnorm
nonspecif
chest
xray
find
seen
patient
mer
abnorm
iti
includ
unilater
bilater
bronchovascular
shadow
interstiti
infiltr
reticular
opac
reticulonodular
shadow
nodul
pleural
effus
patchi
confluent
consolid
appendix
pp
lower
lobe
tend
affect
upper
lobe
earli
cours
mer
rapid
opacif
lung
progress
acut
respiratori
distress
syndrom
occur
highresolut
ct
might
show
ground
glass
opac
figur
earli
ct
find
without
consolid
follow
interlobular
septal
intralobular
interstiti
thicken
peripher
lower
lobe
involv
within
first
week
merscov
infect
subsequ
week
socal
crazypav
lung
abnorm
cavit
treeinbud
pattern
centrilobular
nodul
constrict
oblit
bronchiol
bronchiol
obliteran
peribronchiolar
airtrap
thick
ene
peripher
bronchiol
organis
pneumonia
observ
current
specif
antimerscov
therapi
avail
human
use
mainstay
clinic
manag
mer
case
mostli
symptom
focus
provid
support
care
pain
fever
manag
treat
concomit
secondari
bacteri
infect
support
vital
organ
function
mild
mer
case
manag
home
predict
factor
develop
pneumonia
includ
older
age
year
high
fever
thrombocytopenia
lymphopenia
creactiv
protein
greater
equal
mgdl
high
viral
load
sputum
threshold
cycl
valu
rrtpcr
respiratori
failur
acut
kidney
injuri
haematuria
proteinuria
common
among
patient
admit
hospit
care
sever
diseas
requir
mechan
ventil
extracorpor
membran
oxygen
dialys
sever
empir
treatment
studi
sever
ill
patient
therapi
use
sever
ill
patient
mer
includ
convalesc
plasma
corticosteroid
antivir
agent
eg
interferon
ribavirin
proteas
inhibitor
combin
member
group
systemat
review
public
therapeut
agent
use
mer
treatment
variou
outbreak
show
complet
absenc
accur
evid
base
emphasis
need
control
trial
sever
agent
shown
inhibitori
effect
merscov
cell
cultur
includ
interferon
ribavirin
ciclosporin
mycophenol
acid
empir
lopinavirritonavir
pegyl
interferon
ribavirin
use
seriou
case
efficaci
data
yet
avail
ongo
randomis
clinic
trial
progress
saudi
arabia
miracl
trial
compar
lopinavirritonavir
recombin
interferon
beta
standard
support
care
placebo
standard
support
care
patient
laboratoryconfirm
mer
requir
hospit
admiss
recurs
multicentr
placebocontrol
doubleblind
randomis
control
trial
design
includ
two
compon
consist
two
stage
first
twostag
compon
design
adjust
sampl
size
determin
futil
stop
efficaci
stop
second
twostag
compon
design
determin
efficaci
stop
possibl
readjust
sampl
size
use
plasma
patient
mer
made
full
recoveri
convalesc
plasma
requir
clinic
trial
evalu
preclin
anim
data
show
transfer
serum
sampl
merscovimmun
camel
infect
mice
result
reduc
weight
loss
lung
histo
patholog
thu
suggest
therapeut
potenti
korean
outbreak
three
patient
mer
respiratori
failur
given
four
infus
convalesc
plasma
two
three
show
neutralis
activ
donor
plasma
plaqu
reduct
neutralis
test
prnt
titr
meaning
serolog
respons
convalesc
plasma
infus
prnt
titr
author
conclud
effect
convalesc
plasma
infus
patient
mer
donor
plasma
neutralis
activ
prnt
titr
greater
equal
use
antibiot
therapi
commonli
start
empir
serious
ill
patient
retrospect
studi
patient
mer
found
macrolid
therapi
result
reduct
mortal
faster
merscov
rna
clearanc
compar
treat
macrolid
seriou
case
hospit
inpati
care
requir
reduc
risk
complic
organ
failur
secondari
infect
noninvas
ventil
associ
high
failur
rate
patient
acut
hypoxaem
respiratori
failur
due
merscov
infect
patient
sever
symptom
might
need
manag
intens
care
unit
lungprotect
ventilatori
strategi
acut
respiratori
di
tress
syndrom
inotrop
support
antimicrobi
therapi
coinfect
renal
replac
therapi
acut
renal
failur
provid
studi
show
benefit
use
system
corticosteroid
system
corticosteroid
shown
delay
viral
clearanc
critic
ill
patient
merscov
infect
rang
potenti
treatment
consider
develop
evalu
panel
phase
firstinhuman
singl
site
randomis
doubleblind
placebocontrol
studi
evalu
safeti
toler
pharmacokinet
immunogen
singl
ascend
dose
coadminist
monoclon
antibodi
administ
intraven
healthi
adult
volunt
ongo
studi
durat
approxim
month
anoth
studi
compar
patient
receiv
extracorpor
membran
oxygen
ecmo
support
receiv
ecmo
support
sever
monoclon
polyclon
neutralis
antibodi
product
includ
novel
chimer
camel
human
heavychain
antibodi
protect
anim
model
potenti
use
preexposur
postexposur
prophylaxi
outbreak
manag
requir
evalu
control
trial
mental
health
studi
patient
quarantin
show
symptom
anxieti
report
feel
anger
week
quar
antin
mental
health
support
accur
inform
appropri
suppli
includ
food
cloth
accommod
provid
peopl
feel
isol
sever
studi
report
diseas
sever
mortal
risk
factor
data
patient
middl
east
south
korea
ahm
colleagu
collect
daili
inform
merscov
case
post
onlin
saudi
arabian
ministri
health
dec
nov
review
laboratoryconfirm
case
mer
show
mortal
day
day
overal
patient
older
year
like
die
mortal
infect
younger
patient
sever
factor
associ
sever
diseas
high
mortal
rate
patient
mer
factor
includ
male
sex
comorbid
preexist
ill
obes
diabet
mellitu
cancer
chronic
heart
lung
kidney
diseas
immunocompromis
state
low
serum
albumin
thrombocytopenia
lymphopenia
concomit
infect
posit
plasma
merscov
rna
receptor
upregul
lung
smoker
patient
chronic
obstruct
pulmonari
diseas
might
explain
patient
comorbid
lung
diseas
prone
sever
ill
korean
outbreak
casefat
rate
patient
die
inhospit
mortal
patient
mortal
symptom
onset
seven
mortal
host
factor
associ
mortal
outbreak
older
age
year
smoke
histori
preexist
pneumonia
abnorm
renal
function
comorbid
low
albumin
alter
mental
high
pneumonia
sever
index
score
admiss
risk
factor
mortal
studi
longterm
effect
recoveri
mer
patient
sever
ill
admit
intens
care
report
higher
limit
measur
qualiti
life
patient
less
sever
ill
manag
medic
ward
longterm
consequ
mer
ill
survivor
appear
similar
caus
viral
caus
sever
acut
respiratori
infect
influenza
parainfluenza
metapneumoviru
followup
imag
studi
patient
recov
mer
indic
lung
fibrosi
might
develop
substanti
number
patient
prevent
transmiss
merscov
commun
healthcar
set
crucial
prevent
outbreak
spread
sever
substant
review
guidelin
avail
subject
import
maintain
good
person
environment
hygien
implement
stringent
contact
droplet
precaut
among
healthcar
worker
prevent
commun
transmiss
contact
trace
quarantin
isol
close
contact
public
educ
import
measur
hospit
earli
case
detect
follow
isol
essenti
ideal
neg
pressur
isol
room
main
infect
prevent
control
measur
manag
patient
mer
well
document
sar
epidem
experi
manag
mer
outbreak
appendix
pp
advanc
technolog
vaccin
platform
clinic
trial
design
bioinformat
support
merscov
vaccin
develop
appendix
pp
target
product
profil
merscov
vaccin
call
develop
three
type
mer
vaccin
human
vaccin
longterm
protect
peopl
high
exposur
risk
healthcar
worker
work
potenti
infect
camel
human
vaccin
reactiv
use
outbreak
set
dromedari
camel
vaccin
prevent
zoonot
tran
mission
multipl
type
vaccin
candid
develop
includ
inactiv
whole
viru
live
attenu
viru
viral
vector
vaccin
subunit
vaccin
dna
vaccin
vaccin
use
protein
domain
protein
requir
bind
host
immunogen
sinc
neu
tralis
antibodi
mostli
direct
receptor
bind
domain
food
agricultur
organ
un
world
organ
anim
health
consult
global
mer
commun
identifi
knowledg
gap
prioriti
mer
research
surveil
manag
control
panel
sever
recent
public
highlight
import
onehumanenvironmentalanimalhealth
one
health
approach
tackl
control
spread
merscov
appendix
p
conclus
merscov
pathogen
epidem
potenti
continu
caus
sporad
human
diseas
remain
blueprint
prioriti
list
given
merscov
appear
highli
endem
among
dromedari
camel
geograph
widespread
area
middl
east
africa
zoonot
transmiss
consequ
risk
human
epidem
like
continu
year
come
merscov
endem
atrisk
countri
must
invest
surveil
public
health
research
medic
interventionsinclud
human
camel
vaccin
develop
continu
risk
human
merscov
outbreak
year
first
discoveri
effect
human
camel
merscov
vaccin
appear
ideal
way
prevent
continu
spread
merscov
dromedari
camel
middl
east
human
high
risk
acquir
commun
nosocomi
merscov
infect
paper
conceptualis
zam
az
author
contribut
equal
literatur
search
write
review
manuscript
declar
compet
interest
